1
-ATPases are ion pumps of fundamental importance in maintaining the electrochemical gradient essential for neuronal survival and function. Mutations in ATP1A3 encoding the a3 isoform cause rapid-onset dystonia-parkinsonism (RDP). We report a de novo ATP1A3 mutation in a patient with typical RDP, consisting of an in-frame insertion of a tyrosine residue at the very C terminus of the Na 1 /K 1 -ATPase a3-subunit-the first reported RDP mutation in the C terminus of the protein. Expression studies revealed that there is no defect in the biogenesis or plasma membrane targeting, although cells expressing the mutant protein showed decreased survival in response to ouabain challenge. Functional analysis demonstrated a drastic reduction in Na 1 affinity in the mutant, which can be understood by structural modelling of the E1 and E2 conformations of the wild-type and mutant enzymes on the basis of the strategic location of the C terminus in relation to the third Na 1 binding site. The dramatic clinical presentation, together with the biochemical findings, provides both in vivo and in vitro evidence for a crucial role of the C terminus of the a-subunit in the function of the Na 1 
INTRODUCTION
Inherited dysfunction of cation pumps has been associated with neurological disorders in humans. The Na þ /K þ -ATPase is a protein complex that exchanges Na þ and K þ ions across the plasma membrane coupled to ATP hydrolysis, a key step for electrical excitability, neurotransmitter transport, volume regulation and other vital cellular functions. The four isoforms of the Na þ /K þ -ATPase a-subunit have a cell-specific and developmentally regulated expression pattern. Heterozygous mutations in ATP1A2, the gene coding for the a2-isoform, cause familial hemiplegic migraine type 2 (FHM2), familial infantile convulsions and common forms of migraine (1 -3) , whereas mutations in the a3-isoform gene ATP1A3 cause the rare movement disorder rapid-onset dystonia-parkinsonism (RDP), also named DYT12 (MIM#128235) (4) . RDP is characterized by acute onset of dystonia and bradykinesia with rostro-caudal gradient and bulbar involvement, usually presenting in adolescents or young adults (5, 6) . The pathophysiological mechanism underlying RDP, in particular the abrupt onset of the extrapyramidal syndrome, is unknown.
Functional studies on wild-type and mutant proteins are helping to elucidate the role of different isoforms of the Na þ /K þ -ATPase both in normal function and disease. The a1-subunit mediates the active transport of Na þ -K þ in the resting membrane. During neural excitation, the a2-subunit contributes to the initial fast uptake of extracellular K þ , whereas a3 is involved in slower post-stimulus recovery (7) . When compared with FHM, in RDP ion gradient has been less studied, however Na þ affinity seems to be mainly impaired without significant reduction in K þ affinity (8) . How this dysfunction of ion transport leads to the characteristic clinical symptoms and time-course of the disease still needs to be understood. An altered uptake of dopamine secondary to the abnormal Na þ gradient has been suggested (8) . The Na þ /K þ -ATPase belongs to the P-type ATPases that hydrolyze ATP through the formation of a phosphorylated intermediate. During the functional cycle, these enzymes undergo large conformational changes between so-called E1 and E2 forms (in Na þ /K þ -ATPase equivalent to Na þ -and K þ -forms, respectively). The first X-ray crystal structure of an Na þ /K þ -ATPase was reported recently for the pig renal enzyme in the E2 conformation with two Rb þ ions bound as K þ congeners (9) . The a-subunit contains the catalytic site for ATP hydrolysis as well as the sites for binding and translocation of the ions. In addition, the Na þ /K þ -ATPase consists of a b-subunit responsible for the structural and functional maturation of the a-subunit and its targeting to the plasma membrane, as well as a regulatory subunit belonging to the FXYD membrane proteins. Most pathogenic ATP1A3 mutations reported thus far are missense mutations (4, 6) . Here, we describe a novel sporadic RDP ATP1A3 mutation leading to the insertion of one additional tyrosine residue at the very end of the C-terminal tail of the protein. Expression studies, cell survival assays, molecular modelling and functional evaluation of Na þ affinity were performed to investigate potential pathophysiological mechanisms.
RESULTS

Identification of a novel ATP1A3 mutation in a patient with sporadic RDP
A 16-year-old female Galician patient presented abruptly with inhibition, bradykinesia, dystonic limb posture, dysphagia, speech difficulties and abnormal gait. She had a previously uneventful medical history, no exposure to drugs or toxins and negative family history for neurological disorders (10) . Since the patient fulfilled the diagnostic criteria proposed for RDP and mutations in ATP1A3 had been reported in this disorder, we sequenced the complete coding region of ATP1A3. We found no mutation in DYT1, GCH1 and PARK2, alternative genes causing dystonia or parkinsonism (data not shown). In the patient, we found an in-frame duplication of three nucleotides at the end of exon 23, immediately before the stop codon. This mutation, c.3191_3193dupTAC, leads to the addition of a third tyrosine residue in the C terminus, p.1013Ydup ( Fig. 1A and B) . The C terminus is highly conserved among Na þ /K þ -pump isoforms, orthologues and paralogues (Fig. 2) . The mutation was not present in either parent, indicating that it arose de novo. Non-paternity was excluded by genotyping 13 microsatellite markers in several autosomes (data not shown). The presence of the three-nucleotide insertion in the patient and lack thereof in her healthy relatives was further confirmed by fluorescent fragment analysis (Fig. 1C) . Additionally, the mutation was not found in 218 control individuals.
The p.1013Ydup mutation decreases cell survival in response to ouabain challenge without altering protein level Given the strong genetic evidence that the tyrosine-encoding three-nucleotide insertion is pathogenic, we examined the functional consequences of this mutation by cell viability assay using ouabain, which inhibits endogenous Na þ /K þ -ATPases. When treated with ouabain, cells expressing ouabain-resistant wild-type pump (a3OR) thrived, whereas cells expressing ouabain-sensitive wild-type pump (a3WT) showed markedly reduced survival (3.5%, normalized to a3OR viability). We then introduced the mutation p.1013Ydup into a3OR. When the endogenous pump is inhibited by ouabain, survival of cells transfected with the mutant, ouabain-insensitive construct a3OR-Ydup depends on the functionality of the expressed exogenous enzyme. Assays of the ouabain-resistant mutant a3OR-Ydup-transfected HeLa cells demonstrated a 71% reduction in survival compared with a3OR cells (Fig. 3A) , suggesting that the p.1013Ydup mutation impaired pump function. Co-expression of . We then went on to determine whether the haploinsufficiency was due to an impaired protein function, reduced protein expression or both. Confocal imaging of the p.1013Ydup transfected cells demonstrated comparable expression of the wild-type and mutant pump in the plasma membrane, with the bulk of the protein retained in the cytoplasm (data not shown). Western blot analysis of HeLa cells grown in ouabain-containing medium showed comparable, biotinylated membrane fraction of wild-type and mutant pumps in relation to the total amount (Fig. 3C ).
The p.1013Ydup causes a 50-fold decrease in Na 1 affinity
Despite the reduced functionality of the mutant enzyme evident from the impaired cell viability, it was nevertheless possible to expand and isolate transfected COS cell lines expressing the mutant Na þ /K þ -ATPase under ouabain selection pressure, where the ouabain sensitive endogenous COS cell Na þ /K þ -ATPase is silenced, thus indicating that the mutant is sufficiently active with respect to Na þ and K þ transport to support cell growth. This allowed us to perform a functional characterization of the mutant enzyme in the plasma membrane fraction, and the affinity for Na þ was determined by measuring the phosphorylation from [g-32 P]ATP at various Na þ concentrations, both for the a2 and a3 isoforms. As seen in Figure 4 , either isoform displayed a striking 40-50-fold reduction in Na þ affinity upon insertion of the additional tyrosine at the C terminus. Molecular modelling of ATP1A3 in the E1 (Na 1 bound) conformation provides a structural basis for the reduced Na 1 affinity
The crystal structure of the Na þ /K þ pump was recently reported for the K þ -binding E2 conformation, showing that the C terminus is recognized by a binding pocket between the transmembrane (TM) segments TM5, TM7 and TM8 (9) . In the same work, it was also demonstrated that truncation of the most C-terminal five amino acid residues (KETYY) interfered with Na þ binding in the E1 form, for which the structure is unknown, thus suggesting an important role of the C terminus in Na þ binding by stabilization of the so-called 'third' Na þ binding site. The present results reveal an even larger effect on Na þ binding of the insertion of an additional tyrosine. To understand how this effect is brought about we built structural models of the wild-type and mutated a3 isoform of the human Na þ /K þ -ATPase in both the E2 and E1 conformations. For both models (WT and Ydup) in the E2 conformation, the C terminus interacts with TM segment TM5 and with the cytoplasmic loop connecting TM segments TM8 and TM9. Our modelling of the E1 conformations shows that such interactions are likely to occur in the Na þ bound form as well, but are destabilized in this form when the extra tyrosine is inserted (Fig. 5) , leading to alterations in the third Na þ site. On the contrary, the extra tyrosine can easily be accommodated in the K þ bound E2 form without destabilization of the TM segments, thus predicting very little effect of the insertion mutation on K þ binding, but a large effect on Na þ binding, in accordance with our experimental observations.
DISCUSSION
We report a sporadic patient with typical RDP due to a novel in-frame insertion mutation in ATP1A3. The combination of symptoms and signs in this patient, described in detail elsewhere (10) , was compatible with the phenotypic spectrum reported in RDP which includes motor and non-motor manifestations such as depression and social phobia (6, 11) . Only a few mutations have been so far identified in RDP, most of them missense mutations in the TM region of the enzyme, at the TM domain-P domain or P domain-N domain interface of the a-subunit (4, 6) . This is the first RDP mutation reported in the C-terminal end of the protein, and the first insertion mutation in ATP1A3. Recently, an in-frame deletion in TM4 was described, which removes one of a pair of leucine residues, but no functional studies are so far available on this mutant (12) . Although most cases of RDP with confirmed ATP1A3 mutation are consistent with autosomal dominant inheritance, other patients with de novo mutations in ATP1A3 have been reported (6, 12, 13) , suggesting that this category of mutations may not be uncommon in this disorder, a fact that needs to be taken into account in the study of sporadic patients with extrapyramidal symptoms and for correct genetic counselling.
In the cell viability assays survival of cells transfected with the mutant, ouabain-insensitive construct a3OR-Ydup was drastically reduced compared with a3OR cells. The effect of p.1013Ydup appears to be conserved, as we observed a similar reduction in cell survival when the mutation was introduced into ATP1A2. Prior studies had also demonstrated that some missense RDP mutations impaired cell viability to a variable extent (4). The present results for the p.1013Ydup mutation, with a lack of active interference of the mutant allele on the wild-type allele, are consistent with a mechanism of haploinsufficiency of RDP-causing mutations and argue against a dominant-negative effect, although this result cannot necessarily be extrapolated to the human brain. Transfection studies with other ATP1A3 mutations identified no defects in plasma membrane targeting but showed differences in total a3 expression among different genotypes, suggesting that reduced a3 stability may contribute to the functional deficit, together with reduced protein activity (4). For the p.1013Ydup mutation, the absence of a discernable difference in the overall protein expression or cell membrane fraction between a3OR-Ydup and a3OR suggests that reduction in cell survival resulted from altered pump function not related to biogenesis, protein stability or plasma membrane targeting. The results of our functional studies indicate that the additional tyrosine residue at the C-terminal end cause a major reduction in Na þ affinity of the enzyme. Only for a few missense mutations, the effects on the interaction with Na þ and K þ have been studied, and in these cases, a reduced Na þ affinity was found (8) . It is striking that the p.1013Ydup mutation revealed here likewise resulted in impairment of Na þ binding, in fact, the largest reduction in Na þ affinity ever reported for any Na þ /K þ -ATPase mutant. This may not be a coincidence, but may be taken as an indication that an increase in the intracellular Na þ concentration is an important part of the pathophysiological mechanism of RDP.
As in other P-type ATPases, the catalytic region of the Na þ / K þ -ATPase is composed of the cytoplasmic phosphorylation (P), nucleotide binding (N) and actuator (A) domains of the a-subunit. The sites binding the transported Rb þ ions were identified in the TM region of the a-subunit, and a putative site for binding the third Na þ ion in the E1 conformation was suggested to be located nearby. The crystal structure further suggested unexpectedly that the C terminus of the a-subunit is strategically located in relation to the third Na þ site within a pocket between TM helices. Indeed, deletion of the five most C-terminal residues, including the terminal tyrosines in tandem, demonstrated a reduction of Na þ affinity (9). Our data provide in vivo and experimental evidence of a key role of the C terminus of the Na þ /K þ -ATPase in the regulation of cation traffic through the cell membrane. Previous structural modelling of E1 and E2 states of the Na þ /K þ -ATPase ion binding sites did not include the C terminus (14) . Our current analysis provides new insights into the structural role of this fragment. Interestingly, a mutation resulting in the addition of 28 residues to the C terminus of ATP1A2 (Â1021R) causing hemiplegic migraine gave rise to severe changes in cation transport and voltage sensitivity (15) . When compared with the 28 amino acid elongation of ATP1A2, the p.1013Ydup mutation in ATP1A3 described here is expanded by just one residue and yet critically affects Na þ transport. Altogether, these data reveal a crucial influence of the Na þ /K þ -ATPase C terminus on ion gradient maintenance. How a similar effect on the Na þ transport by the pump leads to such different disorders as hemiplegic migraine and RDP (the a3 mutation reported here) is intriguing. It may be related to different functions, cell-type or development-specific expression patterns of the a2 and the a3 subunits of the Na þ /K þ -ATPase. In the adult brain, the a2 isoform is mostly expressed in glial cells, whereas the a3 isoform is expressed in neurons but not in the glia (16, 17) . Although the non-motor symptoms such as psychiatric manifestations described in some RDP patients may reflect the broad neuronal distribution of a3 (6), the typical presentation of RDP indicates a selective affectation of cortical -subcortical circuits of motor control.
Changes in intracellular Na þ can result in secondary changes in Ca 2þ via the Na þ /Ca 2þ exchange system with consequences for signalling cascades. It might be possible that disturbance of the Na þ gradient, the driving force for uptake of key neurotransmitters, could impair dopamine uptake. However, positron emission tomography imaging in RDP compared with idiopathic Parkinsońs disease shows that RDP patients do not have impairment of the dopamine re-uptake system (18) . Furthermore, single photon emission computed tomography with 123I-Ioflupane (DAT-SCAN) was normal in the patient reported here (10), as well as in another RDP patient (19) , demonstrating that the problem in RDP is not the decrease of CNS dopaminergic activity, which explains lack of response to levodopa in these patients (6) . Alternatively, Na þ /Ca 2þ misbalance may affect other neurotransmitters and cause abnormal firing of specific neurons which might then be vulnerable to selective triggers. Irregular and spontaneous bursts of neuronal discharges occur in the medial globus pallidus in patients with dystonia (20, 21) , altering the basal ganglia outflow to the motor cortex and, in turn, the descending regulation of inhibitory interneuronal mechanisms originating the essential feature of dystonia: co-contraction of agonist and antagonist muscles (22) . Our data support that an increased cortical motor excitability and/or disruption of basal ganglia inhibitory control due primarily to a misbalance in Na þ concentration may result in the dystonic, bradykinetic movement disorder in RDP without significant involvement of the dopaminergic system. Channel dysfunction and disrupted ion homeostasis has also been invoked as the aetiology of paroxysmal dyskinesias, a group of disorders with either spontaneous or triggered episodes of dystonia where ion channel modulators are generally helpful (23) . Interestingly, both paroxysmal dystonia and RDP patients may associate epilepsy (6, 23) and mutations in ion channel genes or leading to altered intracellular ion concentration have been found in patients with epilepsy and paroxysmal dyskinesias (24 -26) .
In summary, we report a novel sporadic mutation at the C-terminal end of ATP1A3 in a patient with RDP. The p.1013Ydup mutation is completely different in nature (in frame insertion) and location (extreme C terminus) from any previously described ATP1A3 mutations. Expression and functional studies show a striking effect of the Y duplication on Na þ affinity of the pump supporting, with in vivo and in vitro evidence, an important functional role for the C terminus of the Na þ /K þ -ATPase a-subunit in the regulation of ion transport. Impaired ion pump function leading to increased intracellular Na þ and inability to maintain normal membrane potential appears to be a key pathophysiological mechanism.
MATERIALS AND METHODS
Genetic studies
Genomic DNA was extracted from the patient and healthy relatives after informed consent following standard procedures. All coding exons and exon -intron boundaries of the ATP1A3 gene were PCR-amplified, bi-directional sequencing was performed with the BigDye Terminator v3.1 Sequencing kit, purified with the Montage SEQ96 Sequencing Reaction Cleanup kit (Millipore) and run in a 3730Âl DNA Analyzer (Applied Biosystems). The presence of the mutation was checked in 218 control individuals. Further confirmation of the mutation was carried out by amplification with fluorescently labelled primers and fragment sizing in the 3730Âl DNA Analyzer. Primer sequences and PCR conditions are available from the authors upon request. Coding of the mutation is relative to the transcript sequence NM_152296 and protein sequence NP_689509. Non-paternity was excluded by genotyping 13 microsatellite markers on multiple chromosomes. Mutation analysis of other genes was performed by sequencing the complete coding region of GCH1 and PARK2. The three-nucleotide DYT1 deletion was excluded by sequencing of exon 5.
Site-directed mutagenesis and cell survival assay
Full length human ATP1A3 cDNA clones, both wild-type (a3WT) and ouabain-resistant (a3OR, with two mutations Q108R and N119D to confer ouabain resistance), housed in pcDNA4/HisMaxC (Invitrogen) were generously provided by Dr L. Ozelius. Using the a3OR cDNA as template, we performed site-directed mutagenesis (QuikChangewII XL Site-Directed Mutagenesis Kit, Stratagene) to introduce the c.3191_3193dupTAC mutation (a3OR-Ydup) confirmed by bi-directional sequencing. The equivalent mutation was introduced into a full-length ouabain-resistant ATP1A2 clone as previously described (27) . HeLa cells were grown in MEMþFBS, at 378C, 5% CO 2 . Transfection with various a2 and a3 constructs was performed with Lipofectamine 2000. To inhibit the endogenous ion pump activity, 1 day after transfection, cells were treated with the Na þ /K þ -ATPase inhibitor ouabain at 1 mM. Cell viability was quantified at 48 h after the ouabain challenge using the 3-(4,5-dimethylthiazol-2-yl-)-2,5-diphenyltetrazolium bromide reduction assay.
Immunoblot and immunocytochemistry
Total protein (10 mg per lane) was subjected to SDSpolyacrylamide gel electrophoresis and transferred to NitroBind Pure Nitrocellulose membranes (Osmonics). The membranes were exposed to monoclonal anti-Xpress (tagged ATP1A3) antibody (Invitrogen) and monoclonal anti-GAPDH antibody (Millipore) for 2 h at room temperature in separate incubations. Incubation with the secondary antibody, horseradish peroxidase conjugated horse anti-mouse, followed for 1 h at RT. Proteins were visualized with the Western Lightning Chemiluminescence Reagent Plus Kit (Perkin Elmer) on Hyperfilm autoradiography (Amersham Life Science). Equivalent volumes were loaded for the membrane fractions before the protein was subjected to electrophoresis through a 4 -12% gradient gel. The blots were probed with anti-GAPDH antibodies as a loading control.
One or two days after transfection, HeLa cells were fixed with 4% paraformaldehyde in PBS for 20 min and then blocked with 6% BSA for 30 min at 378C. Cells were incubated with a mouse anti-Xpress antibody (Invitrogen) for 1 h at RT, followed by incubation with Alexa 594-conjugated goat anti-mouse antibody (Invitrogen) for 1 h at RT. Epifluorescent microscopy was performed using Olympus BX-51 and confocal fluorescent microscopy with Leica TCS SP MP inverted microscope.
Assessment of Na
1 affinity COS-1 cells were transfected with the human a2-WT-OR, a3-WT-OR, a2-WT-OR-Y1013dup or a3-WT-OR-Y1013dup cDNA constructs. Ouabain-resistant colonies expressing the exogenous ouabain-resistant human Na 1 /K 1 -ATPases were selected by growth in the presence of 5 mM ouabain and expanded into stable cell lines (8) . A crude plasma membrane fraction was prepared from transfected COS-1 cells grown in medium containing ouabain, and was made leaky by use of sodium deoxycholate. Studies of the Na þ dependence of phosphorylation from [g-32 P]ATP were carried out on the leaky membrane suspension (10 mg total membrane protein preincubated with ouabain to inhibit the endogenous enzyme) at 08C as previously described (8) . The acid-precipitated 32 P-labelled phosphoenzyme was washed by centrifugation, subjected to SDS-polyacrylamide gel electrophoresis at pH 6.0, and the radioactivity associated with the separated Na þ / K þ -ATPase band was quantified by 'imaging' using a Packard Cyclone TM Storage Phosphor System.
Molecular modelling of the a3-isoform of human Na Structures of the E1 and E2 conformations of the human ATP1A3, for both wild-type and mutant containing the extra tyrosine insertion, were generated by means of the homology modelling software Modeller v9.3 (28) . For the E2 forms, the recently reported structure of the pig Na þ /K þ -pump (3B8E) was used as the only template, the modelling process was straightforward (sequence identity between the two species is 85%). For the modelling of the E1 (Na þ bound) state, we used different template structures for different parts of the protein: the closely related structure of SERCA in the E1 conformation (1VFP) (29) was used as the template for the main body of the pump, whereas for the C-terminal segment we used as additional template the corresponding structure of the Na þ /K þ -pump. The necessary alignment between SERCA and the Na þ /K þ -ATPase was obtained by structural alignment with STAMP (30) using the experimental E2 conformations of the two proteins. In all cases, the best out of five models was selected on the basis of stereochemistry and energetic criteria combined with visual inspection.
